Johnson & Johnson share#snapshot#suffix 943981 / US4781601046
261.49
USD
5.03
USD
1.96 %
09.10.2026
BTT
| prices + charts + realtime | news + analysis | fundamental | company | corresponding shares | action | |
|---|---|---|---|---|---|---|
| price + Chart | chart (large) | news + ad-hoc | balance sheet/p&l | fixed dates | certificates | portfolio#add_instrument_to#depot |
| times + sale | chart comparison | analysis | detailnavigation#shares#estimates | profile | portfolio#add_instrument_to#watchlist | |
| stock exchange | realtime push | stock price appreciation potential | dividend/annual shareholders' meeting | |||
| shares#detailnavigation#orderbook | analysis | |||||
| historic | ||||||
prices + charts + realtime
news + analysis
fundamental
company
corresponding shares
Johnson Johnson Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2025 | Johnson & Johnson | 2.48 | 5.14 | USD |
| 2024 | Johnson & Johnson | 3.39 | 4.91 | USD |
| 2023 | Johnson & Johnson | 3.00 | 4.70 | USD |
| 2022 | Johnson & Johnson | 2.52 | 4.45 | USD |
| 2021 | Johnson & Johnson | 2.45 | 4.19 | USD |
| 2020 | Johnson & Johnson | 2.53 | 3.98 | USD |
| 2019 | Johnson & Johnson | 2.57 | 3.75 | USD |
| 2018 | Johnson & Johnson | 2.78 | 3.54 | USD |
| 2017 | Johnson & Johnson | 2.38 | 3.32 | USD |
| 2016 | Johnson & Johnson | 2.73 | 3.15 | USD |
share#balance#profitpershare- Johnson & Johnson
| 11.0 25 | 5.8 24 | 13.7 23 | 6.7 22 | 7.8 21 | 5.5 20 | 5.6 19 |
share#balance#salespershare- Johnson & Johnson
| 38.8 25 | 36.6 24 | 33.3 23 | 35.7 22 | 35.1 21 | 30.9 20 | 30.6 19 |
share#balance#p_e_ratio- Johnson & Johnson
| 18.8 25 | 25.1 24 | 28.3 23 | 26.2 22 | 21.9 21 | 28.6 20 | 25.9 19 |
Johnson & Johnson: share#balance#headline#theshare (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 |
| Gewinn je Aktie (unverwässert) | 11.13 | 5.84 | 5.59 | 6.83 | 7.93 | 5.59 | 5.72 |
| Gewinn je Aktie (verwässert) | 11.03 | 5.79 | 5.53 | 6.73 | 7.81 | 5.51 | 5.63 |
| Dividende je Aktie | 5.14 | 4.91 | 4.70 | 4.45 | 4.19 | 3.98 | 3.75 |
| Veränderung Dividende je Aktie in % | 4.68 | 4.47 | 5.62 | 6.21 | 5.28 | 6.13 | 5.93 |
| share#balance#cell#dividend_payment | 12’381.00 | 11’823.00 | 11’770.00 | 11’682.00 | 11’032.00 | 10’481.00 | 9’917.00 |
Johnson & Johnson: share#balance#business_ratio (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| share#balance#cell#sales_share | 38.77 | 36.56 | 33.26 | 35.67 | 35.06 | 30.92 | 30.59 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 18.82 | 25.05 | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 |
| KGV (Jahresendkurs, Gewinn verwässert) | 18.82 | 25.05 | 28.32 | 26.23 | 21.91 | 28.57 | 25.88 |
| share#balance#cell#dividend_ratio | 2.48 | 3.39 | 3.00 | 2.52 | 2.45 | 2.53 | 2.57 |
| share#balance#cell#equity_ratio | 40.93 | 39.69 | 41.04 | 40.99 | 40.67 | 36.18 | 37.70 |
| share#balance#cell#debt_ratio | 59.07 | 60.31 | 58.96 | 59.01 | 59.33 | 63.82 | 62.30 |
Johnson & Johnson: share#balance#headline#income_statement (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| share#balance#cell#sales | 94’178.00 | 88’819.00 | 85’152.00 | 95’015.00 | 93’758.00 | 82’572.00 | 82’113.00 |
| share#balance#cell#sales_change | 6.03 | 4.31 | -10.38 | 1.34 | 13.55 | 0.56 | 0.71 |
| share#balance#cell#sales_gross_profit | 64’626.00 | 60’957.00 | 58’722.00 | 64’297.00 | 63’884.00 | 54’574.00 | 54’978.00 |
| share#balance#cell#sales_gross_profit_change | 6.02 | 3.81 | -8.67 | 0.65 | 17.06 | -0.73 | 1.16 |
| share#balance#cell#operating_income | 26’124.00 | 20’823.00 | 22’162.00 | 24’780.00 | 24’481.00 | 20’468.00 | 21’550.00 |
| share#balance#cell#operating_income_change | 25.46 | -6.04 | -10.56 | 1.22 | 19.61 | -5.02 | 1.40 |
| share#balance#cell#income_before_tax | 32’581.00 | 16’687.00 | 15’062.00 | 21’725.00 | 22’776.00 | 16’497.00 | 17’328.00 |
| share#balance#cell#income_before_tax_change | 95.25 | 10.79 | -30.67 | -4.61 | 38.06 | -4.80 | -3.73 |
| share#balance#cell#income_after_tax | 26’804.00 | 14’066.00 | 13’326.00 | 17’941.00 | 20’878.00 | 14’714.00 | 15’119.00 |
| share#balance#cell#income_after_tax_change | 90.56 | 5.55 | -25.72 | -14.07 | 41.89 | -2.68 | -1.16 |
Johnson & Johnson: share#balance#headline#balance (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 117’666 | 108’614 | 98’784 | 110’574 | 107’995 | 111’616 | 98’257 |
| Langzeit Gesamtverbindlichk. je Aktie | 26.39 | 24.22 | 21.81 | 20.96 | 23.88 | 26.26 | 23.66 |
| share#balance#cell#total_equity | 81’544 | 71’490 | 68’774 | 76’804 | 74’023 | 63’278 | 59’471 |
| share#balance#cell#total_equity_change | 14.06 | 3.95 | -10.46 | 3.76 | 16.98 | 6.40 | -0.47 |
| share#balance#cell#total_liabilities_and_equity | 199’210 | 180’104 | 167’558 | 187’378 | 182’018 | 174’894 | 157’728 |
| share#balance#cell#total_liabilities_and_equity_change | 10.61 | 7.49 | -10.58 | 2.94 | 4.07 | 10.88 | 3.12 |
Johnson & Johnson: share#balance#headline#other_data (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 11.13 | 5.84 | 5.59 | 6.83 | 7.93 | 5.59 | 5.72 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 90.55 | 4.48 | -18.17 | -13.84 | 41.93 | -2.22 | 0.28 |
| Gewinn je Aktie (verwässert) | 11.03 | 5.79 | 5.53 | 6.73 | 7.81 | 5.51 | 5.63 |
| Veränderung Gewinn je Aktie (verwässert) in % | 90.56 | 4.63 | -17.83 | -13.74 | 41.72 | -2.18 | 0.40 |
| share#balance#cell#employees | 140’800 | 139’800 | 131’900 | 152’700 | 141’700 | 134’500 | 132’200 |
| share#balance#cell#employees_change | 0.72 | 5.99 | -13.62 | 7.76 | 5.35 | 1.74 | -2.15 |
Johnson & Johnson Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Johnson & Johnson | Quartalszahlen | 13.10.2026 |
| Johnson & Johnson | Quartalszahlen | 26.01.2027 |
| Johnson & Johnson | Quartalszahlen | 20.04.2027 |
| Johnson & Johnson | Quartalszahlen | 21.07.2027 |
| Johnson & Johnson | Quartalszahlen | 19.10.2027 |
Johnson & Johnson vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q2 2026 Earnings Release | 15.07.2026 |
| Hauptversammlung | Annual General Meeting | 23.04.2026 |
| Quartalszahlen | Q1 2026 Earnings Release | 14.04.2026 |
| Quartalszahlen | Q4 2025 Earnings Release | 21.01.2026 |
| Quartalszahlen | Q3 2025 Earnings Release | 14.10.2025 |
| Quartalszahlen | Q2 2025 Earnings Release | 16.07.2025 |
| Hauptversammlung | Annual General Meeting | 24.04.2025 |
| Quartalszahlen | Q1 2025 Earnings Release | 15.04.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 22.01.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 15.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 17.07.2024 |
| Hauptversammlung | Annual General Meeting | 25.04.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 16.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 23.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 17.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 20.07.2023 |
| Hauptversammlung | Annual General Meeting | 27.04.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 18.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 24.01.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 18.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 19.07.2022 |
| Hauptversammlung | Annual General Meeting | 28.04.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 19.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 25.01.2022 |
share#companyprofile#balance#staff#headline
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| share#companyprofile#balance#staff#employees | 132’200 | 134’500 | 141’700 | 152’700 | 131’900 |
| share#companyprofile#balance#staff#salesperemployee | 0.62 | 0.61 | 0.66 | 0.62 | 0.65 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| share#companyprofile#balance#staff#currentassets | 45’274 | 51’237 | 60’979 | 55’294 | 53’495 |
| share#companyprofile#balance#staff#fixedassets | 112’454 | 123’657 | 121’039 | 132’084 | 114’063 |
| share#companyprofile#balance#staff#totalassets | 157’728 | 174’894 | 182’018 | 187’378 | 167’558 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| share#companyprofile#balance#staff#totalborrowing | 98’257 | 111’616 | 107’995 | 110’574 | 98’784 |
| share#companyprofile#balance#staff#totalequity | 59’471 | 63’278 | 74’023 | 76’804 | 68’774 |
| share#companyprofile#balance#staff#totalliabilities | 157’728 | 174’894 | 182’018 | 187’378 | 167’558 |
shares#companyprofile#address#headline
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| phone | +1 (732) 524-0400 |
| internet | http://www.jnj.com |
management
|
Cynthia F. Yee
Vice President-Strategy & New Growth Platforms |
|
Daniel E. Pinto
Independent Director |
|
Elizabeth Forminard
Chief Legal Officer & Executive Vice President |
|
Eugene A. Woods
Independent Director |
|
George Davy
Director-Global Human Resources |
|
Hubert Joly
Independent Director |
|
James D. Swanson
Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jessica Moore
Group Chief Financial Officer-Innovative Medicine |
|
Joaquin Duato
Chairman & Chief Executive Officer |
|
John C. Reed
Executive Vice President-Innovative Medicine |
|
John George Morikis
Independent Director |
|
Jonathan Sheh
Director-Workplace Experience |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Kathryn E. Wengel
Chief Technical Operations & Risk Officer |
|
Kristen Blair Mulholland
Chief Human Resources Officer & Executive VP |
|
Marc Larkins
Secretary & Vice President-Worldwide Governance |
|
Marillyn A. Hewson
Lead Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Nadja Y. West
Independent Director |
|
Paula A. Johnson
Independent Director |
|
Penny M. Heaton
Chief Medical Officer |
|
Robert J. Decker
Chief Accounting Officer & Controller |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Ryan Koors
Vice President-Investor Relations |
|
Sid Jain
VP-Global Development Data Science |
|
Thomas J. Spellman
Secretary |
|
Timothy Schmid
Executive Vice President & Chairman-Worldwide |